Neuroprotection Strategies In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuroprotection refers to therapeutic strategies aimed at preserving neuronal structure and function, slowing or preventing neuronal death, and maintaining neural circuit integrity in the context of neurodegenerative diseases. Unlike disease-modifying therapies that target specific pathological proteins (e.g., amyloid-beta/proteins/amyloid or alpha-synuclein/proteins/alpha, neuroprotective approaches focus on bolstering intrinsic neuronal survival mechanisms, reducing cellular stress, and enhancing the brain's resilience to insult.[1]
Despite decades of research, no therapy has achieved definitive neuroprotection in a major neurodegenerative disease clinical trial. However, advances in understanding the molecular mechanisms of neuronal death — including mitochondrial dysfunction, oxidative stress, excitotoxicity, neuroinflammation, and protein aggregation — have yielded an expanding pipeline of neuroprotective candidates. As of 2025, a paradigm shift is underway from purely symptomatic treatment toward more holistic and proactive approaches emphasizing neuroprotection, disease modification, and patient-centric solutions.[2]
Neuroprotective strategies target one or more of the following cell death pathways:
Mitochondrial dysfunction is a hallmark of virtually all neurodegenerative diseases. Impaired oxidative phosphorylation, excessive reactive oxygen species (ROS production, defective mitophagy, and disrupted calcium buffering contribute to neuronal energy failure. Neuroprotective strategies include:
oxidative stress — the imbalance between ROS production and antioxidant defenses — causes lipid peroxidation, protein oxidation, and DNA damage in neurons. Approaches include:
Edaravone: FDA-approved free radical scavenger for ALS. The oral formulation (Radicava ORS) received approval in 2022, improving patient access. However, a 2024 post-marketing analysis suggested that long-term clinical benefit may be modest[4]
N-acetylcysteine (NAC): Glutathione precursor and antioxidant — Phase 2 trials in PD showed improved dopamine transporter binding on DaT-SPECT
Nrf2 activators: Dimethyl fumarate (FDA-approved for MS) and sulforaphane activate the Nrf2-ARE pathway, upregulating endogenous antioxidant enzymes (heme oxygenase-1, NAD(P)H quinone oxidoreductase 1, glutathione S-transferase). Nrf2 activation is being explored for AD and PD neuroprotection[15]
ferroptosis inhibitors: Iron chelators (deferiprone) and lipid peroxidation inhibitors targeting the recently characterized ferroptotic cell death pathway
N-acetylcysteine (NAC): Glutathione precursor and antioxidant
Nrf2 activators: Dimethyl fumarate and sulforaphane activate the Nrf2-ARE pathway, upregulating endogenous antioxidant enzymes
ferroptosis inhibitors: Iron chelators and lipid peroxidation inhibitors### Excitotoxicity
excitotoxicity — neuronal death caused by excessive glutamate receptor activation — contributes to neurodegeneration through calcium overload and downstream activation of proteases, lipases, and endonucleases. Approaches include:
Chronic neuroinflammation driven by activated microglia are in Phase 2 for AD (INVOKE-2 trial)[7]
neuroinflammation-targeted therapies: TNF-α inhibitors, IL-1β blockers, complement inhibitors
NLRP3 inflammasome inhibitors: The NLRP3 inflammasome is a key driver of chronic neuroinflammation in AD, PD, and ALS. While MCC950 (the most studied preclinical inhibitor) was discontinued due to hepatotoxicity, next-generation inhibitors including dapansutrile (OLT1177) and inzomelid are advancing through clinical trials with improved safety profiles[16]
Microglial modulators: Shifting [disease-associated microglia (DAM) toward homeostatic states
JAK/STAT inhibitors: Reducing inflammatory signaling cascades — baricitinib and tofacitinib are being repurposed for neuroinflammatory conditions
TREM2 agonists: Enhancing beneficial microglial phagocytosis and reducing harmful inflammation [7]
neuroinflammation-targeted therapies: TNF-α inhibitors, IL-1β blockers, complement inhibitors
Microglial modulators: Shifting disease-associated microglia (DAM) that enhance autophagy. The REACH trial is testing rapamycin for AD prevention based on its pro-autophagic and anti-inflammatory effects[8]
autophagy-enhancing therapies/treatments/autophagy-enhancing-therapies): TFEB activators (trehalose, curcumin analog C1) that upregulate the master transcription factor for lysosomal biogenesis and autophagy
Targeted protein degradation (PROTACs): Directing specific toxic proteins to proteasomal degradation — tau]-PROTACs and alpha-synuclein-PROTACs are in preclinical development
[Chaperone-mediated autophagy] enhancers: Targeting the selective degradation pathway for specific proteins via LAMP-2A upregulation
Declining levels of neurotrophic factors contribute to neuronal vulnerability. Strategies include:
BDNF delivery: Gene therapy or protein delivery to enhance neurotrophin levels — AAV-BDNF gene therapy is in early clinical trials for AD
GDNF delivery: Particularly relevant for dopaminergic neurons in Parkinson's disease. The convection-enhanced delivery trial showed target engagement but mixed clinical results, leading to dose optimization studies[9]
Small-molecule neurotrophin mimetics: TrkB agonists (7,8-DHF, LM22A-4), p75NTR modulators — offering the advantage of oral bioavailability over protein-based approaches
GLP-1 receptor agonists: Semaglutide and liraglutide show neuroprotective properties in preclinical models and are being tested in AD and PD trials. The ELAD Phase 2b trial (2024) demonstrated that liraglutide reduced brain volume loss by nearly 50% in memory-related regions and slowed cognitive decline by up to 18% compared to placebo. The larger EVOKE Plus trial (3-year, 1,800+ patients) is testing semaglutide in early AD with results expected in late 2025[10]
BDNF delivery: Gene therapy or protein delivery to enhance neurotrophin levels
GDNF delivery: Particularly relevant for dopaminergic neurons in Parkinson's disease [9]
Small-molecule neurotrophin mimetics: TrkB agonists (7,8-DHF), p75NTR modulators
GLP-1 receptor agonists: Semaglutide and liraglutide show neuroprotective properties in preclinical models and are being tested in AD and PD trials [10]## Antisense Oligonucleotide and Gene-Based Neuroprotection
ASOs represent a transformative neuroprotective approach by silencing the expression of toxic gain-of-function proteins at the mRNA level:
Gene therapy enables targeted delivery of neuroprotective genes directly to vulnerable brain regions, providing sustained neuroprotection without systemic side effects:[9]
Gene therapy enables targeted delivery of neuroprotective genes (e.g., GDNF, NRTN, GBA1) directly to vulnerable brain regions, providing sustained neuroprotection without systemic side effects [9].## Non-Pharmacological Neuroprotection
Regular aerobic exercise is the most consistently supported neuroprotective intervention, with evidence from both observational studies and randomized controlled trials:[11]
Increased BDNF production and hippocampal neurogenesis — high-intensity interval training (HIIT) may be more effective than moderate continuous exercise for BDNF elevation
Improved cerebral blood flow and neurovascular unit function
Enhanced mitochondrial biogenesis and antioxidant defenses via PGC-1α activation
Reduced neuroinflammation through IL-6-mediated anti-inflammatory myokine release
The ADEX trial (2024) showed that moderate-to-high-intensity exercise reduced tau] PET signal in early AD participants
In PD, the Park-in-Shape and SPARX trials demonstrated that vigorous exercise slows motor progression (reduced UPDRS-III decline by ~1.5 points/year)
Increased BDNF production and hippocampal neurogenesis
Improved cerebral blood flow and neurovascular unit function
Enhanced mitochondrial biogenesis and antioxidant defenses
Reduced neuroinflammation
Exercise and Neuroprotection — see dedicated page [11]### Cognitive Engagement and Cognitive Reserve
Cognitive stimulation, education, and intellectually demanding activities build "cognitive reserve" — the brain's ability to compensate for pathology. Higher cognitive reserve is associated with delayed onset of dementia symptoms despite similar pathological burden. The cognitive reserve concept has been quantified through the Stern Cognitive Reserve Index, which predicts AD onset timing independent of amyloid/tau biomarker status.[12]
[Sleep disruption] impairs [glymphatic clearance] of toxic proteins. Optimizing sleep quality may be neuroprotective by enhancing waste clearance, reducing neuroinflammation, and promoting synaptic homeostasis. Suvorexant (a dual orexin receptor antagonist) reduced CSF amyloid-beta and phosphorylated tau levels during sleep in a 2023 randomized trial, suggesting that sleep-targeted interventions may have disease-modifying potential.
The Mediterranean diet, MIND diet, and ketogenic diets have shown neuroprotective associations in epidemiological studies. Specific dietary components with neuroprotective evidence include:
Senolytics — drugs that selectively eliminate senescent cells — are being tested for neuroprotection. The combination of dasatinib + quercetin is in clinical trials for Alzheimer's disease, targeting cellular senescence as a driver of neuroinflammation and neurodegeneration. The SToMP-AD pilot trial (2022) showed that the combination was safe and achieved CNS penetration based on CSF biomarker changes; a larger Phase 2 trial is now ongoing.[13]
Declining NAD+ levels with aging impair mitochondrial function, DNA repair, and sirtuin activity. NAD+ precursors are in clinical trials for neuroprotection:[3]
A 2025 comprehensive review in Signal Transduction and Targeted Therapy highlighted anti-aging interventions as a new frontier in neuroprotection:[18]
Stem cell therapy approaches include direct neuronal replacement and "bystander effects" — transplanted neural stem cells secrete neurotrophic factors, modulate inflammation, and enhance endogenous repair mechanisms. Recent advances include iPSC-derived dopaminergic neuron transplantation for PD (Phase 1/2 trials by BlueRock Therapeutics, 2024) and MSC-derived exosome therapy for ALS.[14]
Rather than combining separate drugs, MTDLs are single molecules designed to simultaneously modulate multiple targets:[19]
Transcranial approaches represent a drug-free neuroprotective strategy:
The study of Neuroprotection Strategies In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.